Brief: Verastem Oncology Doses First Patient In Target-D 201 Phase 2 Registration-Directed Trial Of Versus-7375 Oral Kras G12d (On/Off) Inhibitor
16/06/2026 21:04
BRIEF-Verastem Oncology Doses First Patient In Target-D 201 Phase 2 Registration-Directed Trial Of Versus-7375 Oral Kras G12d (On/Off) Inhibitor June 16 (Reuters) - Verastem Inc VSTM.O:
VERASTEM ONCOLOGY DOSES FIRST PATIENT IN TARGET-D 201 PHASE 2 REGISTRATION-DIRECTED TRIAL OF VERSUS-7375 ORAL KRAS G12D (ON/OFF) INHIBITOR FOR KRAS G12D-MUTATED METASTATIC PANCREATIC CANCER
Source text: ID:nBw5W1GhDa
Further company coverage: VSTM.O
((Reuters.Briefs@thomsonreuters.com;))